The way that Poet has been treated by the markets reminds me of the way Special Purpose Acquisition Companies SPACS have been treated by the markets recently.
Some good companies have been thrown out with the trash.
Poet has a list of great products moving into production, unlike many biotechs.
Why can the markets not see that?